Article: Monitoring what governments "give for" and "spend on" vaccine procurement: Vaccine Procurement Assistance and Vaccine Procurement Baseline

Background: The Global Vaccine Action Plan will require, inter alia, the mobilization of financial resources from donors and national governments - both rich and poor. Vaccine Procurement Assistance (VPA) and Vaccine Procurement Baseline (VPB) are two metrics that could measure government performance and track resources in this arena. VPA is proposed as a new subcategory of Official Development Assistance (ODA) given for the procurement of vaccines and VPB is a previously suggested measure of the share of Gross Domestic Product (GDP) that governments spend on their own vaccine procurement.

Objective: To determine realistic targets for VPA and VPB.

Methods: Organization for Economic Co-Operation and Development (OECD) and World Bank data for 2009 were analyzed to determine the proportions of bilateral ODA from the 23 Development Assistance Committee (DAC) countries disbursed (as % of GDP in current US$) for infectious disease control. DAC country contributions to the GAVI Alliance for 2009 were assessed as a measure of multilateral donor support for vaccines and immunization programs.

Findings: In 2009, total DAC bilateral ODA was 0.16% of global GDP and 0.25% of DAC GDP. As a percentage of GDP, Norway (0.013%) and United Kingdom (0.0085%) disbursed the greatest proportion of bilateral ODA for infectious disease control, and Norway (0.024%) and Canada (0.008%) made the greatest contributions to the GAVI Alliance. In 2009 0.02% of DAC GDP was US$7.61 billion and 0.02% of the GDP of the poorest 117 countries was US$2.88 billion.

Conclusions: Adopting 0.02% GDP as minimum targets for both VPA and VPB is based on realistic estimates of what both developed and developing countries should spend, and can afford to spend, to jointly ensure procurement of vaccines recommended by national and global bodies. New OECD purpose codes are needed to specifically track ODA disbursed for a) vaccine procurement; and b) immunization programs.

Citing Articles

Vaccine Procurement: A Conceptual Framework Based on Literature Review.

Gianfredi V, Filia A, Rota M, Croci R, Bellini L, Odone A Vaccines (Basel). 2021; 9(12).

PMID: 34960180 PMC: 8707219. DOI: 10.3390/vaccines9121434.

How much money is spent on vaccines across Western European countries?.

Ethgen O, Baron-Papillon F, Cornier M Hum Vaccin Immunother. 2016; 12(8):2038-2045.

PMID: 27224429 PMC: 4994728. DOI: 10.1080/21645515.2016.1155013.

The cost of vaccination throughout life: A western European overview.

Ethgen O, Cornier M, Chriv E, Baron-Papillon F Hum Vaccin Immunother. 2016; 12(8):2029-2037.

PMID: 27050111 PMC: 4994732. DOI: 10.1080/21645515.2016.1154649.

References

1.

Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M . Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012; 12:878. PMC: 3532196. DOI: 10.1186/1471-2458-12-878. View

2.

Greco G, Powell-Jackson T, Borghi J, Mills A . Countdown to 2015: assessment of donor assistance to maternal, newborn, and child health between 2003 and 2006. Lancet. 2008; 371(9620):1268-75. DOI: 10.1016/S0140-6736(08)60561-9. View

3.

Wolfson L, Gasse F, Lee-Martin S, Lydon P, Magan A, Tibouti A . Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ. 2008; 86(1):27-39. PMC: 2647343. DOI: 10.2471/blt.07.045096. View

4.

Gandhi G, Lydon P, Cornejo S, Brenzel L, Wrobel S, Chang H . Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020. Vaccine. 2013; 31 Suppl 2:B137-48. DOI: 10.1016/j.vaccine.2013.01.036. View

5.

Pitt C, Greco G, Powell-Jackson T, Mills A . Countdown to 2015: assessment of official development assistance to maternal, newborn, and child health, 2003-08. Lancet. 2010; 376(9751):1485-96. DOI: 10.1016/S0140-6736(10)61302-5. View

6.

Powell-Jackson T, Borghi J, Mueller D, Patouillard E, Mills A . Countdown to 2015: tracking donor assistance to maternal, newborn, and child health. Lancet. 2006; 368(9541):1077-87. DOI: 10.1016/S0140-6736(06)69338-0. View

7.

Barnighausen T, Bloom D, Cafiero E, OBrien J . Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012; 18 Suppl 5:70-6. DOI: 10.1111/j.1469-0691.2012.03977.x. View

8.

Nelson E, Yu L . Poverty focused assistance: new category of development aid. Lancet. 1996; 348(9042):1642-3. DOI: 10.1016/s0140-6736(96)06389-1. View

9.

Mahoney R, Ramachandran S, Xu Z . The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine. 2000; 18(24):2625-35. DOI: 10.1016/s0264-410x(00)00073-6. View

10.

De la Hoz-Restrepo F, Castaneda-Orjuela C, Paternina A, Alvis-Guzman N . Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines. Vaccine. 2013; 31 Suppl 3:C80-7. DOI: 10.1016/j.vaccine.2013.05.064. View

11.

Hsu J, Pitt C, Greco G, Berman P, Mills A . Countdown to 2015: changes in official development assistance to maternal, newborn, and child health in 2009-10, and assessment of progress since 2003. Lancet. 2012; 380(9848):1157-68. DOI: 10.1016/S0140-6736(12)61415-9. View

Monitoring What Governments "give For" and "spend On" Vaccine Procurement: Vaccine Procurement Assistance and Vaccine Procurement Baseline